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Background and purpose: To analyze erectile function in men treated by prostate brachytherapy (PB) for localized
prostate cancer.
Material and methods: Of a series of 270 sexually active men treated by PB, 241 (89%), mean age 65 yr (range,
43–80 yr), participated in a study on erectile function that was evaluated using the International Index of Erectile
Function 5-item (IIEF-5) questionnaire before implantation and by postal survey after a mean follow-up of
36 months (range, 6–70 months).
Results: After PB, 27 patients (11%) had no erectile dysfunction (ED), 36 (15%) had mild ED, 58 (24%) had mild to
moderate ED, 24 (10%) had moderate ED, 53 (22%) had severe ED and 43 (18%) were not sexually active. In
patients with a preimplant IIEF score >12 (cut-off for intercourse with penetration), 73% had a deterioration of
erectile function by at least one class after PB. Risk factors for ED after PB were age, preimplant IIEF score and
prostate volume. Median time to ED onset was 16 months and was shorter with androgen deprivation (p = 0.007),
diabetes (p = 0.03) and age over 55 (p = 0.01).
Conclusions: Following PB, the majority of patients progressively develop or major ED after a free interval that may
last several months.
Support: Ligue Nationale contre le Cancer, France
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Objet: Etude de la fonction érectile chez les hommes traités par curiethérapie pour un cancer localisé de la
prostate.
Matériels et Méthodes: A partir de 270 hommes sexuellement actifs, traités par curiethérapie, 241 (89%), moyenne
d’âge 65 ans (entre, 43–80 ans), acceptaient de participer à l’étude de la fonction érectile après curiethérapie. Cette
étude menée par le questionnaire validé IIEF 5 (International Index of Erectile Function 5-item), évaluait la fonction
érectile avant curiethérapie, et en moyenne 36 mois (entre 6-70mois) après la curiethérapie de prostate. L’enquête
était faite par envoi postal.
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Résultats: Après la curiethérapie, 27 patients (11%) n’avaient pas de dysfonction érectile, 36 (15%) avaient une
dysfonction très modérée, 58 (24%) entre très modérée et modérée, 24 (10%) modérée, 53 (22%) avaient une
dysfonction érectile sévère et 43 (18%) n’étaient plus sexuellement actifs. Parmi les patients ayant un score IIEF
avant curiethérapie >12 (score moyen permettant une pénétration pendant l’acte sexuelle), 73% avait une
détérioration de leur fonction érectile d’au moins une classe IIEF. Les facteurs de risque de la dysfonction érectile
après curiethérapie étaient: l’âge, le score IIEF avant curiethérapie et le volume de la prostate.
La période moyenne pour déclencher une dysfonction érectile après curiethérapie était de 16 mois. Cette période
se réduisait lorsque les patients étaient sous hormonothérapie (p = 0.007), avaient du diabète (p = 0.03) et étaient
âgés de plus de 55 ans (p = 0.01).
Conclusions: Après curiethérapie, la majorité des patients développaient progressivement une dysfonction érectile
plusieurs mois après la curiethérapie.
Soutien: Ligue Nationale contre le Cancer, France
Mots clés: Érection, Curiethérapie, Function sexuelle, Questionnaire, Cancer de la prostateIntroduction
In Europe as well as in North America, carcinoma of the
prostate (CaP) is the most frequent cancer in men before
lung cancer [1,2]. Moreover, its incidence has been in-
creasing during recent decades and continues to rise.
Thanks to efforts toward early diagnosis, CaP is mostly
diagnosed at an early stage. Until now, comparison of
different treatments according to long-term oncological
results has been controversial [3], putting functional as-
pects at the forefront in decision counseling. Erectile
dysfunction (ED) is a major preoccupation for CaP pa-
tients, especially younger ones. In a series of men treated
for localized CaP 12 to 24 months previously, Bokhour
et al. found that ED affected not only the quality of sex-
ual intimacy, but also everyday interaction with women,
sexual imaging and fantasy life, and manliness percep-
tion [4]. A meta-analysis of 54 articles concluded that
the predicted probability of maintaining erectile function
was 0.76 after prostate brachytherapy (PB), 0.60 after PB
plus external beam radiotherapy, 0.55 after external
beam radiotherapy, 0.34 after nerve-sparing radical pros-
tatectomy and 0.25 after standard radical prostatectomy
[5]. However none of the articles analyzed were random-
ized controlled trials, some of the studies did not reflect
current standards of treatment and none of the PB studies
had a follow-up longer than 2 years. The latter point is cru-
cial in view of the possibility of delayed deterioration of
erectile function following radiation treatments [6,7]. How-
ever, so far, observations of changes over time of the preva-
lence of ED after PB remain controversial. Stock et al.
found that the proportion of potent men decreased over
time following PB (79% at 3 years, 59% at 6 years) [8].
Valicenti et al. observed that after PB, one patient on two
had ED, but that dysfunction resolved within one year after
treatment [9]. Finney et al. found no significant correlation
between the proportion of men with ED and time since
implantation, with a median follow-up of 2.5 years [10].The recommendations of the American Brachytherapy
Society illustrate this uncertainty, concluding that both
severity and duration of morbidities after treatment may
vary from one patient to another [11].
This pleads for a better knowledge of ED after PB, in
order to:
(1)provide patients with fuller information about their
long-term risk of ED,
(2)develop more cost-effective interventions
(3)help in the development of new protocols of clinical
research on ED in this population.
The primary goal of the present study was to analyze
the occurrence of ED after PB and its associated risk fac-




During the study period (2000–2007), the Institut Claudius
Régaud cancer center, Toulouse was the unique center in
the Midi-Pyrénées region (South West France) to perform
prostate brachytherapy. Therefore, all the patients’ candi-
date for this modality of treatment were referred by urolo-
gists to this center.
Inclusion criteria were CaP stage T1c/T2N0M0, Gleason
score ≤ 7 (3 + 4), PSA < 10 ng/ml, prostate volume < 50 cc,
no history of trans-urethral resection of the prostate, and
index of prostatic symptom score (IPSS) < 8.
Between 2000 and 2006, 316 consecutive patients were
implanted with radioactive iodine 125I seeds using a
real-time ultrasound-based planning technique (real-
time computer-assisted dosimetry with dynamic seed
localization performed in the operating room). The pre-
scribed brachytherapy dose was 160.5 Gy. According to
the post treatment dosimetry, the mean dose to 90% of
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the mean percentage of prostate volume receiving at
least 100% of the prescribed dose (V100) was 88%. Sixty-
three (26%) patients received neoadjuvant androgen
deprivation therapy for a mean of 4 months (range 2 to
24 months). No patient received supplemental external
beam radiation therapy or surgery potentially damaging
to erectile function. A questionnaire on sexual activity
(including the IIEF-5 questionnaire) was systematically
completed by the patients before the beginning of treat-
ment (during the preimplant consult).
Survey
We performed our survey of sexual dysfunction in
November 2006. All patients who were sexually active
before PB were contacted by mail irrespectively of
whether or not they had a committed partner. An intro-
ductory letter was mailed to the patients that included
the questionnaire, the name of the research contact per-
son and phone numbers for further information. Evalua-
tions were completed by mail and a reminder letter was
sent if questionnaires were not returned within four
weeks. Anyway, each patient completed only one post-
treatment questionnaire.
Of the 316 patients, 28 men who were not sexually ac-
tive before PB, eight who needed a second implantation
and 10 who had died (of causes unrelated to cancer)
were excluded. After treatment, the 270 eligible patients
were asked to participate in the survey of sexual dys-
function and were considered as agreeing to participate
if they completed the questionnaire. Only 29 refused to
take part (participation rate: 89%). Finally, we obtained
information about sexual function before and after PB in
241 patients. We checked that there were no significant
differences in demographic, medical and PB parameters
between responders and non-responders (Table 1). Tables 2
and 3 summarize the characteristics of the population who
participated in the study (n = 241) and their treatment pa-
rameters. The mean interval between the end of treatment
and post-treatment survey was 36 months (range 6 to
70 months).
Measures
Demographic and medical measures
Sociodemographic data, disease and treatment charac-
teristics were recorded prospectively.
Measurement of erectile function
The questionnaire on sexual function covered various
aspects of sexual activity. Here we present only the re-
sults relating to erectile function. The questionnaire was
similar to the pre-treatment inventory of sexual function
in order to be able to compare changes over time.In order not to bias the results due to the use of medi-
cations (notably PDE5 inhibitors), it was stressed in the
introduction letter and in the questionnaire that the pa-
tients had to describe the quality of erection without any
medication, and a special question focused on treatment
for sexual dysfunction. All patients who declared using a
medication (n = 36) were called by phone by a research
assistant to verify their answer.
According to the recommendations of the American
Brachytherapy Society [11], erectile function was
assessed using the IIEF-5 questionnaire (French version)
[12]. To analyze the severity of ED, we used the accepted
classes: a score of 5 to 7 defined severe ED, 8 to 11 mod-
erate ED, 12 to 16 mild to moderate ED, 17 to 21 mild
ED, and a score above 22 no ED [12,13].
Statistical methods
Statistical analysis was done using STATA SE 8.2® (Stata
Corporation College Station, TX) and R version 2.3.1
software and a confidence interval of 95%. Descriptive
statistics were performed for all studied variables with a
normality test for all quantitative variables. Inter-group
comparisons were performed using the chi-2 (or Fisher
exact) test for qualitative variables and the Mann–
Whitney test for quantitative variables. IIEF scores before
and after PB were compared using the Wilcoxon test. As
there were a large number of variables, we first performed
factorial analysis to obtain a graphic representation to re-
veal potential interactions between variables. Associations
between IIEF score and variables were sought with the
Mann–Whitney test and Spearman’s correlation test. ED
risk factors were studied by logistic regression analysis
with adjustment for age, neoadjuvant androgen deprivation
therapy and PSA level. Significant variables in univariate
analysis (threshold at 10%) were analyzed by multivariate
analysis
The log-rank test was used for inter-group compari-
sons. Cox regression was applied to determine the links
between variables and occurrence over time of ED (haz-
ard ratio), when the proportional hazards hypothesis was
verified.
Ethical approval
In accordance with French regulations about clinical re-
search, it was not required to have agreement from an




After implantation, patients had a significantly lower
mean IIEF score than before implantation (13.2 +/− 7.5
vs. 19.1 +/− 5.5; p < 0.0001).
Table 1 Comparison responders - non responders
Responders Non responders
Variables (n = 269) (n = 29) P-value
Age (year) 66,4 ± 7,2 65,6 ± 7,9 0,67
Pre-treatment index of prostatic symptom score (IPSS) 4,1 ± 2,8 4,2 ± 2,8 0,75
Pre-treatment PSA (ng/ml) 6,7 ± 2,3 7,1 ± 2,4 0,32
Pre-treatment prostate volume (cm3) 34,2 ± 9,7 33,7 ± 9,6 0,89
Gleason score (% points) 0,52
< VII 82 79
VII 18 21
Clinical tumour stage (% points) 0,43
T1C 60 72
T2 40 28
Neoadjuvant hormonal therapy (% points) 27,5 38 0,28
Follow-up (year) 3,0 ± 1,5 2,6 ± 1,3 0,24
D90 (minimal dose received by 90% of the prostate gland) 159,8 ± 21,8 151,7 ± 21,7 0,08
U30* (minimal dose received by 30% of urethra) 215,5 ± 44,0 198,5 ± 40,0 0,06
V100* (percentage of the prostate volume receiving 100% of the prescribed dose) 87,7 ± 8,0 85,5 ± 7,6 0,09
V150* (percentage of the prostate volume receiving 150% of the prescribed dose.) 47,5 ± 14,6 43,0 ± 12,0 0,14
RV160* (surface of rectum receiving 160 Gy) 0,58 ± 0,76 0,42 ± 0,55 0,42
Number of implanted seeds 74,2 ± 11,7 72,1 ± 12,6 0,41
Number of implanted needles 21,2 ± 2,7 21,3 ± 3,0 0,87
* measurements 30 days after implantation.
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tion (ED), 65 (27%) had mild ED, 43 (18%) had mild to
moderate ED, 17 (7%) had moderate ED, and 7 (3%) had
severe ED. After PB, 27 patients (11%) had no ED, 36
(15%) had mild ED, 58 (24%) had mild to moderate ED,
24 (10%) had moderate ED, 53 (22%) had severe ED and
43 (18%) were not sexually active.
Of the 216 patients who had a score ≥ 12 before PB
(cut-off for intercourse with penetration), 32 (15%)
ceased to be sexually active after treatment. Of the 184
patients who continued to be sexually active, 46 (25%)
remained in the same IIEF score class, 56 (30%)
downgraded by one class, 78 (42%) by two or more clas-
ses, and 4 (2%) upgraded by one class.
Patients with an IIEF score <12 before PB had a sig-
nificantly higher risk of becoming sexually inactive after
PB (p < 0.001). In the severe ED group before PB, 50%
became sexually inactive after PB.
Risk factors for erectile dysfunction
Factorial analysis
Factorial analysis showed a strong association between
the IIEF score after PB and age at implantation. An IIEF
score < 7 after PB appeared to be linked to the presence
of comorbid conditions (diabetes, obesity, history of car-
diovascular disorders, contraindications to surgery) and/
or neoadjuvant androgen deprivation therapy.Correlations
The IIEF score after PB was correlated with age at im-
plantation (r = 0.18, p = 0.013) and with the IIEF score
before PB (r = 0.47, p < 0.001). On the other hand, it did
not appear to be correlated with PB parameters (D90,
V100, V150, RV160, U30), nor with the length of time
between PB and evaluation. An affirmative response to
the question « At the time you found that you had pros-
tate cancer, was maintaining sexual activity of concern
to you? (yes/no) » was associated with a higher IIEF
score before and after PB (p = 0.0001, p = 0.0182).
Logistic regression
The results of logistic regression were adjusted for age,
neoadjuvant androgen deprivation therapy and PSA
level. Univariate analysis was performed for the follow-
ing variables: age, IIEF score and IIEF classes before PB,
existence of morning erection, concern about sexuality,
neoadjuvant hormonal therapy, pre-treatment PSA level,
IPSS score and prostate volume, history of diabetes,
vascular disorders and obesity, contraindication to sur-
gery, brachytherapy parameters D90, V100, V150, U30,
RV160, number of implanted seeds and number of im-
planted needles. Table 4 summarizes significant risk fac-
tors for erectile dysfunction in univariate analysis. These
were taken into consideration for multivariate analysis
(Table 5). The variables significantly associated with the
Table 2 Characteristics of the population (n = 241)
Mean ± SD (Min-max)
Age (years) 66 ± 7 (43 – 80)
Pre-treatment PSA (ng/mL) 6.6 ± 2.2 (1.2 - 12.6)
Pre-treatment index of prostatic symptom
score (IPSS)
4.0 ± 2.8 (0 – 15)
Pre-treatment prostate volume (cm3) 36.3 ± 9.7 (14 – 67)
N (%)
Gleason score None 10 (4.2)
< 6 43 (17.8)
6 146 (60.6)
7 42 (17.4)




Vascular disorders 46 (19)
Obesity (Body mass Index > 2.8) 22 (9)
Contraindication to surgery 25 (10)
Neoadjuvant hormonal therapy* 63 (26)
* LHRH agonists in 10 patients (15.9%), non-steroidal antiandrogens in 6
(9.5%), cyproterone acetate in 25 (39.7%), and complete androgen blockade in
22 (34.9%).
Table 3 Prostate brachytherapy parameters (n = 241)
Number of implanted seeds
Mean ± SD 74.3 ± 11.6
Min-max 47-111
Number of implanted needles
Mean ± SD 21.4 ± 2.7
Min-max 12-31
D90* (minimal dose received by 90% of the prostate gland)
Mean ± SD 160.5 ± 22.2
Min-max 97.5-222
U30* (minimal dose received by 30% of urethra)
Mean ± SD 215 ± 44.7
Min-max 14.1-395.8
RV160* (surface of rectum receiving 160 Gy)
Mean ± SD 0.56 ± 0.76
Min-max 0-5
V100* (percentage of the prostate volume receiving 100% of the
prescribed dose)
Mean ± SD 88 ± 7.9
Min-max 61.8-99.5
V150* (percentage of the prostate volume receiving 150% of the
prescribed dose)
Mean ± SD 47.5 ± 14.5
Min-max 16.1-84.7
*: measurements 30 days after implantation.
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1.12), IIEF score before implantation (OR = 0.89, 95%
CI = 0.84–0.95) and prostate volume (OR = 0.96, 95%
CI = 0.93–0.99). It was noteworthy that the risk of devel-
oping ED appeared to increase with decreasing prostate
volume.
Timing of onset of erectile dysfunction
With regard to the timing of onset of ED, we carried
out separate analysis of patients who had received
neoadjuvant androgen deprivation therapy. Their time to
onset of ED was significantly shorter (3 vs. 16 months.;
p = 0.007). Univariate Cox regression confirmed that
erectile function deteriorated earlier after neoadjuvant
androgen deprivation therapy (HR = 1.97, 95% CI =
1.32 – 2.93, p = 0.0001). In patients who had not had
neoadjuvant androgen deprivation therapy, 142 were
able to estimate the time to onset of their ED, 30 replied
that they had experienced no deterioration and 6 pa-
tients were unable to state when erectile function had
deteriorated. In patients with diabetes, median time to
onset of ED was 4 months compared with 18 months in
patients without diabetes (log-rank; p = 0.03). An associ-
ation was also found between the rapidity of onset of ED
and age over 55 years (log-rank; p = 0.01). Cox univariate
regression analysis confirmed that the onset of ED after
PB was earlier when the patient had diabetes (hazardratio (HR) = 1.91, 95% CI = 1.12 – 3.25, p = 0.017) or
when he was aged over 55 (HR = 0.43, 95% CI = 0.24 –
0.77, p = 0.005).
Discussion
One of the aims of our study was to clarify the risk of
ED after brachytherapy in order to provide patients with
fuller information. We observed that even if the onset of
erectile deterioration is relatively late (16 months), the
majority of patients described a gradual deterioration of
erectile function: 73% of patients who had an initial IIEF
score greater than 12 downgraded by at least one IIEF
score class at a mean follow-up of 36 months. Merrick
et al. [14], in a series of 128 patients who were potent
before brachytherapy and followed for 29 months, found
that 50.5% maintained potency at 3 years. However,
several remarks may be made: (1) only one of the par-
ticipating centers used the 5-point IIEF score for longi-
tudinal follow-up, whereas the other centers used a
4-point score which was considerably lacking in sensitiv-
ity, and (2) the authors defined maintenance of potency
as an IIEF score of more than 12. This results in a lack
of sensitivity, since decreases of the IIEF score above 12
were not taken into account. Another drawback to using
Table 4 Significant risk factors for erectile dysfunction
after prostate brachytheray in univariate analysis
OR a Standard error 95% CI p-value
Age 1.08 0.023 1.04 – 1.13 <0.001
IIEF score before PB 0.88 0.026 0.83 – 0.93 <0.001
IIEF classes before PB
Severe ED 1.00
Moderate ED 0.78 0.98 0.06 – 9.19 0.842
Mild to moderate ED 0.17 0.193 0.02 – 1.55 0.117
Mild ED 0.10 0.115 0.01 – 0.91 0.041
No DE 0.08 0.085 0.01 – 0.67 0.021
Concern about sexuality
No 1.00
Yes 0.48 0.158 0.25 – 0.91 0.026
Diabetes
No 1.00
Yes 3.47 1.872 1.21 – 9.99 0.021
Prostate volume (cm3) 0.96 0.014 0.94 – 0.99 0.021
a OR adjusted by logistic regression for age, PSA level and neoadjuvant
androgen deprivation therapy (yes/no).
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a downgrade in class, is that this makes evaluation
dependent on erectile function before treatment. (3)
Some of the patients in the study were treated using a
modified brachytherapy technique in which the bulb of
the penis was spared, with the aim of reducing erectile
morbidity. It is therefore difficult to draw from this
study conclusion applicable to the general population of
patients treated by brachytherapy. In a recent study of
Merrick team, in the 226 patients with prostate cancer
and preimplant erectile function assessed by IIEF6, the
7-year actuarial rate potency preservation was 55.6%Table 5 Risk factors for erectile dysfunction after prostate
brachytherapy in multivariate analysis
OR a Standard error 95% CI p-value
Age 1.06 0.025 1.02 – 1.12 <0.001
IIEF before PB 0.89 0.029 0.84 – 0.95 <0.001
Diabetes
No 1.00
Yes 2.60 1.491 0.85 – 8.00 0.094
Prostate volume (cm3) 0.96 0.015 0.93 – 0.99 0.017
Concern about sexuality
Yes 1.00
No 0.73 0.263 0.36 – 1.48 0.380
a The logistic regression model contains the binary variable of erection as
dependent variable and the variables age, PSA level, hormonal treatment, IIEF
score before brachytherapy, diabetes, prostate volume, morning erection and
concern about sexuality as independent variables.with median postimplant IIEF of 22 in potent patients.
Potent patients were statistically younger, had higher
preimplant IIEF and were less likely to be diabetic [15].
Potency preservation and median IIEF scores following
brachytherapy are durable. Thoughtful dose sparing of
proximal penile structures and early penile rehabilitation
may further improve these results [15].
It must be noted that most of the patients of our study
continued to be sexually active (89%). The present re-
sults concern erectile function without any medication,
but Schiff et al. previously showed that sildenafil (PDE5
inhibitor) is effective in this population [16]. In our
population, only 36 in 171 sexually active men with ED
used medication for ED (such as PDE5 inhibitor). These
results plead for the development of interventions for a
better management of ED in this population [17].
Patients at high risk of ED should be particularly
concerned by such interventions. We identified 3 risk
factors for ED: preimplant erectile dysfunction, age and
prostate volume. Prostate volume was the third signifi-
cant factor in the multivariate analysis. The patients with
a small prostate volume had a high risk of severe ED
post PB, independent of the brachytherapy parameters.
In our experience, the imaging technique used to calcu-
late prostate volume (MRI for the patients treated in
Toulouse) does not seem to modify significantly the per-
formance of the model. Several anatomic structures in-
volved in erectile function may be affected by PB in the
case of a small prostate gland, due to an increase risk of
radiation outside of the prostate.
Diabetic patients and those treated by neoadjuvant an-
drogen deprivation should also be implicated as they de-
veloped early ED. Other factors that could be involved
in ED after PB were not explored by the present study:
mictional problems, psychological effects related to the
fear of cancer, apprehension of contaminating the part-
ner, of pain during intercourse or hematospermia. There
is no doubt that such fears could be alleviated by appro-
priate information.
Moreover, we recently showed that PB resulted in
ejaculatory and orgasmic troubles [18]. Taking into ac-
count the high prevalence of sexual dysfunction in pa-
tients treated by PB, we propose developing supportive
interventions in the domain of sexuality to cover the
whole pre-treatment and post-treatment period [19].
Limitations
This is a cohort study and consequently may differ from
the overall population of patients treated by PB. How-
ever, the criteria of patient inclusion and the treatment
modalities used in our centre are widely accepted. Par-
ticipation rate was high and we verified that participants
and men who declined to participate did not differ
according to demographic, disease and treatment
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source of bias.
We cannot rule out the risk of miscalculation related
to evaluation by the patient of the date when erectile
function began to deteriorate. However, most of the
questionnaire uses a validated scale (IIEF-5), which
limits the risk of bias. There was only one evaluation of
erectile function after PB. This is a shortcoming to study
evolution of erectile function in time. Even if our ques-
tionnaire is helpful in understanding of the process of
occurrence of ED after PB, and taking into account that
the mean time of occurrence of ED is late (16 months
after PB), questionnaires should be given at standard in-
tervals of 6-12-18-24 months.
In an elderly population (mean age 66 years), an increase
of ED incidence with age must be taken into account. The
Massachussets Male Aging Study showed that about 10%
of the males of the normal population develop ED due to
the aging process. However, according to studies in com-
munity populations, over a mean period of 3 years the de-
gree of spontaneous deterioration of erectile function
should be limited [20].
Factorial analysis showed that an IIEF score of less than
7 after brachytherapy was related to the presence of concur-
rent disorders: diabetes, obesity, cardiovascular diseases,
medical contraindications to surgery and/or neoadjuvant
androgen deprivation therapy. However, in multivariate
analysis, only age, IIEF score before implantation and pros-
tate volume were found to be significant. Other studies with
larger series are certainly required to provide more precise
knowledge of risk factors for ED after brachytherapy.
Our evaluation does not take several items into account,
such as age of partner or frequency of intercourse. We
project to develop a prospective study including these
shortcomings for further understanding of this important
health related quality of life issue.Conclusion
Patients often choose brachytherapy because it is re-
puted to be less damaging to erectile function. In this
study we observed that 36 months after implantation,
73% of men with a IIEF score more than 12 before PB
had a deterioration of erectile function by at least one
class when measured by the IIEF score. In view of the
high prevalence of ED after PB, information before treat-
ment about this morbidity of PB is mandatory, especially
in patients at high risk of developing ED (age over 65,
preimplant ED and small prostate volume). Our findings
contribute further evidence that ED following PB ap-
pears progressively after a free interval that may last sev-
eral months or even years (mean 16 months). Adequate
management of ED after treatment should be proposed
to patients who wish to maintain sexual function.Abbreviations
PB: Prostate brachytherapy; IIEF: International index of erectile function;
ED: Erectile dysfunction; Gy: Gray; PSA: Prostate specific antigen.
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